上海起發(fā)實(shí)驗(yàn)試劑正規(guī)代理Trilink產(chǎn)品，zui近市場出現(xiàn)Trilink的假貨，為了您的實(shí)驗(yàn)安全請選擇正牌代理。 :

TriLink BioTechnologies——高品質(zhì)常規(guī)/特殊核苷酸產(chǎn)品
TriLink BioTechnologies公司是世界的核酸修飾技術(shù)領(lǐng)域的，成立于1996年，總部設(shè)在San Diego，California。TriLink公司致力于高品質(zhì)核酸修飾產(chǎn)品的研發(fā)和生產(chǎn)，提供包括核苷酸、常規(guī)及核苷三磷酸特殊修飾的寡核苷酸定制（oligonucleotides），m RNA合成，CleanAmp?PCR產(chǎn)品，phosphoramidites和其他小分子在內(nèi)的眾多產(chǎn)品。近二十年來，TriLink一直是診斷和OEM市場核酸產(chǎn)品供應(yīng)的行業(yè)，產(chǎn)品應(yīng)用于基因治療，核苷類化療，寡核苷酸治療和診斷領(lǐng)域。此外，TriLink還可提供特殊核苷酸、m RNA定制，合同研究服務(wù)和ISO/ QSR標(biāo)準(zhǔn)的cGMP生產(chǎn)設(shè)施。TriLink完善的產(chǎn)品及研發(fā)服務(wù)解決方案有助于推動藥物發(fā)現(xiàn)和生物醫(yī)學(xué)研究。

經(jīng)過18年的發(fā)展， TriLink已經(jīng)成為高品質(zhì)RNA合成領(lǐng)域的，為廣大科研工作者提供的mRNA及長鏈RNA（長可達(dá)幾個Kb），并且定制修飾。同時我們也提供成品mRNA產(chǎn)品，包括報(bào)告基因及 mRNA表達(dá)因子。

Genome Editing mRNA

Plasmids and viral vectors have traditionally been used in genome editing to express the required proteins inside cells or an organism. However, editing DNA carries a risk. Double stranded DNA breaks catalyze insertion of DNA at the cut site. At some substantial frequency, the protein expression vectors can integrate, which can lead to continuous expression of the nuclease or a previously silent sequence.

Now mRNA is being used in genome editing to transiently express the required proteins. With no risk of insertional mutagenesis, it is a powerful tool. Additionally synthetic mRNA, which mimics fully processed, capped and polyadenylated mRNA, can be produced in large quantities by in vitro transcription and modified to reduce innate immune stimulation.

產(chǎn)品如下：

Zinc-finger Nuclease mRNA (ZFN mRNA)

Zinc-finger nucleases (ZFNs) were the first widely applicable site specific genome editing tools. Recently, several studies have shown that ZFNs can have off-target effects at non-targeted chromosomal sites that are similar in sequence to the intended target site. For this reason, there is a move to transient ZFN expression using mRNA based vectors. TriLink’s custom mRNA transcription service includes ZFN mRNA. Request a quote today!

L-7206
CleanCap™ Cas9 mRNA (modified)
CleanCap™ CRISPR Associated Protein 9 mRNA (U-modified) 

mRNA Length: 4,521 nucleotides

Concentration: 1.0 mg/mL

Buffer: 1 mM Sodium Citrate, pH 6.4

Identity & Purity:

Agarose Gel Mobility; Pass

Concentration ± 5%; Pass

Product Insert
SDS

Cas9 mRNA expresses a version of the Streptococcus pyogenes SF370 Cas9 protein (CRISPR Associated Protein 9). Cas9 functions as part of the CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) genome editing system. In the CRISPR system, an RNA guide sequence targets the site of interest and the Cas9 protein is employed to perform double stranded DNA cleavage.

Cas9 mRNA encodes the Cas9 protein with an N and C terminal nuclear localization signal (NLS). The incorporation of two NLS signals within the mRNA increases the frequency of delivery to the nucleus, thus increasing the rate of DNA cleavage. Additionally, a C terminal HA epitope tag aids detection, isolation, and purification of the Cas9 protein.

This mRNA is capped using CleanCap™, TriLink's proprietary co-transciptional capping method, which results in the naturally occuring Cap 1 structure with high capping efficiency. It is polyadenylated, substituted with a modified uridine and optimized for mammalian systems. It mimics a fully processed mature mRNA.

Certificate(s) of Analysis

TD-OA02A

T1-CHZ01A-1 

L-7206 is a replacement product for L-6125 and L-6129. 

Not for resale without express written permission. Not for use in humans. No license under any patent or patent pending is granted or implied by the purchase of any TriLink product. TriLink does not warrant that the use or sale of the products delivered hereunder will not infringe the claims of any United States or other patents or patents pending covering the use of the product alone or in combination with other products or in the operation of any process. All and any use of TriLink product is the purchaser’s sole responsibility.

CleanCap™ Cre mRNA (5moU)
CleanCap™ NLS-Cre Recombinase mRNA (5-methoxyuridine) 

Contact us today to preorder! 

Catalog Number: L-7211 

mRNA Length: 1,437 nucleotides

Concentration: 1.0 mg/mL

Buffer: 1 mM Sodium Citrate, pH 6.4

Identity & Purity:

Agarose Gel Mobility; Pass

Concentration ± 5%; Pass

Product Insert
SDS

NLS-Cre Recombinase mRNA is a capped and polyadenylated messenger RNA encoding Cre recombinase fused to a nuclear localization sequence (NLS). Cre recombinase is a tyrosine recombinase that catalyzes recombination between two loxP sites.

This mRNA is capped using CleanCap™, TriLink's proprietary co-transciptional capping method, which results in the naturally occuring Cap 1 structure with high capping efficiency. It is polyadenylated, modified with 5-methoxyuridine and optimized for mammalian systems. It mimics a fully processed mature mRNA.

L-7211 is a replacement for L-6108.

Not for resale without express written permission. Not for use in humans. No license under any patent or patent pending is granted or implied by the purchase of any TriLink product. TriLink does not warrant that the use or sale of the products delivered hereunder will not infringe the claims of any United States or other patents or patents pending covering the use of the product alone or in combination with other products or in the operation of any process. All and any use of TriLink product is the purchaser’s sole responsibility.

L-7606
CleanCap™ Cas9 mRNA
CleanCap™ CRISPR Associated Protein 9 mRNA 

mRNA Length: 4,521 nucleotides

Concentration: 1.0 mg/mL

Buffer: 1 mM Sodium Citrate, pH 6.4

Identity & Purity:

Agarose Gel Mobility; Pass

Concentration ± 5%; Pass

Product Insert
SDS

Cas9 mRNA expresses a version of the Streptococcus pyogenes SF370 Cas9 protein (CRISPR Associated Protein 9). Cas9 functions as part of the CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) genome editing system. In the CRISPR system, an RNA guide sequence targets the site of interest and the Cas9 protein is employed to perform double stranded DNA cleavage.

Cas9 mRNA encodes the Cas9 protein with an N and C terminal nuclear localization signal (NLS). The incorporation of two NLS signals within the mRNA increases the frequency of delivery to the nucleus, thus increasing the rate of DNA cleavage. Additionally, a C terminal HA epitope tag aids detection, isolation, and purification of the Cas9 protein. 

This mRNA is capped using CleanCap™, TriLink's proprietary co-transciptional capping method, which results in the naturally occuring Cap 1 structure with high capping efficiency. It is polyadenylated, and optimized for mammalian systems. It mimics a fully processed mature mRNA.